It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The cyclic five-membered disulfide 1,2-dithiolane has been widely used in chemical biology and in redox probes. Contradictory reports have described it either as nonspecifically reduced in cells, or else as a highly specific substrate for thioredoxin reductase (TrxR). Here we show that 1,2-dithiolane probes, such as “TRFS” probes, are nonspecifically reduced by thiol reductants and redox-active proteins, and their cellular performance is barely affected by TrxR inhibition or knockout. Therefore, results of cellular imaging or inhibitor screening using 1,2-dithiolanes should not be interpreted as reflecting TrxR activity, and previous studies may need re-evaluation. To understand 1,2-dithiolanes’ complex behaviour, probe localisation, environment-dependent fluorescence, reduction-independent ring-opening polymerisation, and thiol-dependent cellular uptake must all be considered; particular caution is needed when co-applying thiophilic inhibitors. We present a general approach controlling against assay misinterpretation with reducible probes, to ensure future TrxR-targeted designs are robustly evaluated for selectivity, and to better orient future research.
Cyclic five-membered disulfides (1,2-dithiolanes) have been reported either as nonspecific redox motifs, or as highly specific cellular probes for thioredoxin reductase (TrxR). Here the authors show that 1,2-dithiolane probes are nonspecifically reduced by a range of thiol reductants and are not sensitive to TrxR modulation, thus they are unsuitable as cellular probes for TrxR.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details







1 Ludwig-Maximilians University Munich, Department of Pharmacy, Munich, Germany (GRID:grid.5252.0) (ISNI:0000 0004 1936 973X)
2 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626)
3 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); Pelago Bioscience AB, Solna, Sweden (GRID:grid.502683.a)
4 Cellular and Molecular Neurobiology, TU Braunschweig, Zoological Institute, Braunschweig, Germany (GRID:grid.6738.a) (ISNI:0000 0001 1090 0254)
5 Justus-Liebig University Giessen, Interdisciplinary Research Centre (IFZ), Giessen, Germany (GRID:grid.8664.c) (ISNI:0000 0001 2165 8627)
6 Karolinska Institutet, Department of Medical Biochemistry, Stockholm, Sweden (GRID:grid.4714.6) (ISNI:0000 0004 1937 0626); National Institute of Oncology, Department of Selenoprotein Research, Budapest, Hungary (GRID:grid.419617.c) (ISNI:0000 0001 0667 8064)